|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
CHIR-99021
|
MedKoo Code#: 200774
|
|
Name: CHIR-99021
|
|
CAS#: 252917-06-9
Synonym:
CHIR-99021
IUPAC/Chemical name:
6-((2-((4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)amino)nicotinonitrile
|
|
Chemical structure |
Theoretical analysis
|
|
|
Chemical Formula: C22H18Cl2N8
Exact Mass: 464.10315
Molecular Weight: 465.34
m/z: 464.10315 (100.0%), 466.10020 (63.9%),
465.10650 (23.8%), 467.10355 (15.2%), 468.09725 (10.2%),
465.10018 (3.0%), 466.10986 (2.7%), 469.10060 (2.4%), 467.09723
(1.9%), 468.10691 (1.7%) .
Elemental Analysis: C, 56.78; H, 3.90; Cl,
15.24; N, 24.08
|
|
Availability and price:
This product is available.
To inquire the quotation
and to order, please send email to
sales@medkoo.com to describe your needs. The product
will be shipped through standard express shipping.
We offer significant discount for bulk orders.
|
|
Information about this agent
|
CHIR99021 inhibits GSK-3 with IC50 at 7 nM. In a
series of carcinoma cell lines, the IC50 of CHIR99021 for proliferation
is about 10uM.
Current developer:
Chiron (Originator)
1: Sineva GS, Pospelov VA. Inhibition of
GSK3beta enhances both adhesive and signaling activities of beta-catenin
in mouse embryonic stem cells. Biol Cell. 2010 Jul 14. [Epub ahead of
print] PubMed PMID: 20626347.
2: Kiyonari H, Kaneko M, Abe S, Aizawa S. Three inhibitors of FGF
receptor, ERK, and GSK3 establishes germline-competent embryonic stem
cells of C57BL/6N mouse strain with high efficiency and stability.
Genesis. 2010 May;48(5):317-27. PubMed PMID: 20162675.
3: Li W, Zhou H, Abujarour R, Zhu S, Young Joo J, Lin T, Hao E, Schöler
HR, Hayek A, Ding S. Generation of human-induced pluripotent stem cells
in the absence of exogenous Sox2. Stem Cells. 2009 Dec;27(12):2992-3000.
PubMed PMID: 19839055.
4: Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J,
Cohen P, Smith A. The ground state of embryonic stem cell self-renewal.
Nature. 2008 May 22;453(7194):519-23. PubMed PMID: 18497825.
5: Tighe A, Ray-Sinha A, Staples OD, Taylor SS. GSK-3 inhibitors induce
chromosome instability. BMC Cell Biol. 2007 Aug 14;8:34. PubMed PMID:
17697341; PubMed Central PMCID: PMC1976608.
6: Terstappen GC, Gaviraghi G, Caricasole A. The Wnt signaling pathway
as a target for the treatment of neurodegenerative disorders. IDrugs.
2006 Jan;9(1):35-8. PubMed PMID: 16374731.
7: Finlay D, Patel S, Dickson LM, Shpiro N, Marquez R, Rhodes CJ,
Sutherland C. Glycogen synthase kinase-3 regulates IGFBP-1 gene
transcription through the thymine-rich insulin response element. BMC Mol
Biol. 2004 Sep 6;5:15. PubMed PMID: 15350195; PubMed Central PMCID:
PMC517930.
8: Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, Ma
ST, Reeder JW, Samuels I, Slabiak T, Wagman AS, Hammond ME, Harrison SD.
Selective glycogen synthase kinase 3 inhibitors potentiate insulin
activation of glucose transport and utilization in vitro and in vivo.
Diabetes. 2003 Mar;52(3):588-95. PubMed PMID: 12606497.
9: Bennett CN, Ross SE, Longo KA, Bajnok L, Hemati N, Johnson KW,
Harrison SD, MacDougald OA. Regulation of Wnt signaling during
adipogenesis. J Biol Chem. 2002 Aug 23;277(34):30998-1004. Epub 2002 Jun
7. PubMed PMID: 12055200.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
